Merck launches Phase 3 CORALreef program for PCSK9 inhibitor MK-0616

Pallavi Madhiraju- August 25, 2023 0

Pharmaceutical giant Merck has announced the initiation of its groundbreaking Phase 3 clinical program, CORALreef, focusing on MK-0616—a novel, oral proprotein convertase subtilisin/kexin type 9 ... Read More

Zydus Lifesciences gets FDA final approval for Pitavastatin Tablets

Pallavi Madhiraju- February 26, 2023 0

Zydus Lifesciences said that it has bagged final approval for Pitavastatin Tablets, 1mg, 2mg, and 4mg from the US Food and Drug Administration (FDA). Pitavastatin ... Read More

AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics

pharmanewsdaily- September 19, 2020 0

Pharma giant AstraZeneca has signed a deal to acquire a preclinical oral PCSK9 inhibitor asset from Dogma Therapeutics, a portfolio company of Viva Biotech. The ... Read More

Novartis to acquire The Medicines Company for $9.7bn with eye on inclisiran

pharmanewsdaily- November 25, 2019 0

Novartis acquisition of The Medicines Company : Swiss drugmaker Novartis signed a deal worth $9.7 billion to acquire US biopharma company The Medicines Company, as ... Read More